Yahoo
NYSE - Nasdaq Real Time Price USD

Veeva Systems Inc. (VEEV)

176.22 +4.86 (+2.84%)
At close: June 29 at 4:03:11 PM EDT
178.89 +2.71 (+1.54%)
Pre-Market: 8:35:14 AM EDT
Trade VEEV on Coinbase
Chart Range Bar
Loading chart for VEEV

News headlines Veeva Systems has recently expanded its AI capabilities by acquiring Copli and launching the Falcon MLR platform, which automates medical, legal, and regulatory reviews. The company is experiencing a strategic shift towards AI, with expectations of significant efficiency improvements and a strong long-term revenue outlook despite current market challenges.

Veeva Systems has recently expanded its AI capabilities by acquiring Copli and launching the Falcon MLR platform, which automates medical, legal, and regulatory reviews. The company is experiencing a strategic shift towards AI, with expectations of significant efficiency improvements and a strong long-term revenue outlook despite current market challenges.

Updated 13m ago · Powered by Yahoo Scout
  • Previous Close 171.36
  • Open 174.46
  • Bid --
  • Ask 178.83 x 20000
  • Day's Range 172.65 - 178.31
  • 52 Week Range 148.05 - 310.50
  • Volume 2,722,248
  • Avg. Volume 3,199,524
  • Market Cap (intraday) 28.626B
  • Beta (5Y Monthly) 0.95
  • PE Ratio (TTM) 31.24
  • EPS (TTM) 5.64
  • Earnings Date (est.) Sep 2, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 244.59

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

www.veeva.com

7,928

Full Time Employees

January 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 6/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VEEV
21.06%
S&P 500 (^GSPC)
8.69%

1-Year Return

VEEV
37.82%
S&P 500 (^GSPC)
20.53%

3-Year Return

VEEV
9.70%
S&P 500 (^GSPC)
69.24%

5-Year Return

VEEV
44.95%
S&P 500 (^GSPC)
73.36%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 882.95M
Earnings 371.14M

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
200M
400M
600M
800M

Analyst Insights

View More

Analyst Price Targets

165.00
244.59 Average
176.22 Current
350.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/4/2026
Analyst Citigroup
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 176 -> 190

Statistics

View More

Valuation Measures

Annual
As of 6/29/2026
  • Market Cap

    28.63B

  • Enterprise Value

    21.42B

  • Trailing P/E

    31.24

  • Forward P/E

    19.61

  • PEG Ratio (5yr expected)

    0.79

  • Price/Sales (ttm)

    8.86

  • Price/Book (mrq)

    3.92

  • Enterprise Value/Revenue

    6.45

  • Enterprise Value/EBITDA

    21.51

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    28.37%

  • Return on Assets (ttm)

    7.30%

  • Return on Equity (ttm)

    13.93%

  • Revenue (ttm)

    3.32B

  • Net Income Avi to Common (ttm)

    941.65M

  • Diluted EPS (ttm)

    5.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.31B

  • Total Debt/Equity (mrq)

    1.41%

  • Levered Free Cash Flow (ttm)

    1.26B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

176.22 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Veeva: Second Acquisition of the Year Highlights Continued Investment in AI Portfolio

    Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

    Rating
    Price Target
  • Lowering target price to $176.00

    Veeva Systems Inc has an Investment Rating of BUY; a target price of $176.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
  • Lowering target price to $180.00

    Veeva Systems Inc has an Investment Rating of BUY; a target price of $180.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
  • Veeva Earnings: Negative Reaction Despite Solid Results and Growing AI Investments Shows Disconnect

    Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: